Artificial intelligence–enabled electrocardiography for assessment of left ventricular systolic dysfunction in the era of foundation models
TL;DR
Adding AI-ECG signals to PREVENT-HF improves near-term heart-failure risk discrimination and reclassification, though without demonstrated benefit on clinical outcomes such as heart-failure hospitalization or mortality.
Abstract
Artificial intelligence (AI) applied to the standard 12-lead electrocardiogram (AI-ECG) is being developed as a scalable approach to screen for left ventricular systolic dysfunction (LVSD) and support triage for confirmatory testing. Supervised models trained on paired ECG–echocardiography data show high discrimination for reduced ejection fraction across thresholds and can identify individuals at higher risk of subsequent LV dysfunction despite a normal baseline echocardiogram. External validation of an FDA-cleared ECG-AI device across four geographically diverse U.S. health systems confirmed strong diagnostic accuracy, though signal-format compatibility and quality gating meaningfully affect real-world yield. Two pragmatic randomized trials demonstrate practice-level impact. In primary care, AI-ECG increased the number of new low-ejection-fraction diagnoses and directed echocardiography preferentially to screen-positive patients. In non-cardiology inpatient wards, AI alerts improved diagnostic yield through increased cardiology consultation rather than increased imaging volume. In emergency-department patients with dyspnea, AI-ECG supports a prioritization role with high negative predictive value, outperforming NT-proBNP, but requires confirmatory imaging given prevalence-dependent positive predictive value. In population cohorts, adding AI-ECG signals to PREVENT-HF improves near-term heart-failure risk discrimination and reclassification, though without demonstrated benefit on clinical outcomes such as heart-failure hospitalization or mortality. Foundation models pretrained on large ECG datasets reduce labeled-data requirements and improve transportability, but prospective echocardiography-anchored validation is required before broader deployment. FDA-cleared software is available for left ventricular ejection fraction ≤40% screening from 12-lead ECGs as clinician decision support. This review summarizes performance across thresholds and care settings, outlines threshold selection and calibration, and defines priorities for outcome-oriented trials, equitable deployment, and implementation governance.